🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "major milestone" in the effort against superbug strains of the bacteria, according to health experts.

A Global Health Concern

Gonorrhoea infections are escalating around the world, with data suggesting more than 82 million instances each year. Particularly high rates are observed in the African continent and countries within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. Within England, cases have reached a record high, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The authorization of fresh medications for gonorrhoea is an critical and opportune development in the context of growing infection rates, escalating drug resistance and the extremely scarce treatment choices currently available.”

Health officials are deeply concerned about the surge in antibiotic-resistant strains. The global health body has listed it as a "high-priority threat". Recent surveillance found that the effectiveness of key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Therapies Gain Clearance

One new antibiotic, alternatively called a brand name, was approved by the American regulatory agency in December for treating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Scientists believe that targeted use of this new drug will help slow the spread of drug resistance.

Gepotidacin, created by the pharmaceutical company GlaxoSmithKline, also received approval in close succession. This treatment, which is employed against urinary tract infections, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin emerged from a innovative non-profit model for medication research. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to bring it to fruition.

“This approval represents a major breakthrough in the treatment of highly resistant gonorrhoea, which previously has been evolving faster than medical innovation.”

Research Study Outcomes and Global Access

As per findings published in a major medical journal, the new drug eradicated over nine in ten of genital gonorrhoea infections. This puts it on an comparable level with the current standard treatment, which involves an injection and a pill. The research included nearly 1,000 patients from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, the non-profit has the ability to register and commercialise the drug in a wide range of low-income and middle-income countries.

Medical professionals on the front lines have voiced hope. The availability of a one-pill regimen of this kind is hailed as a "critical tool" for gonorrhoea control. This is considered essential to reduce the burden of the infection for patients and to halt the transmission of untreatable gonorrhoea around the world.